Celcuity Inc. Schedules Release of Second Quarter 2022 Financial Results and Webcast/Conference Call

Rhea-AI Summary

Celcuity Inc. (NASDAQ:CELC), a biotechnology firm concentrating on targeted therapies for hormonally driven cancers, will release its Q2 2022 financial results on August 11, 2022, after market close. A webcast/teleconference will follow at 4:30 p.m. Eastern Time for discussion of the results and corporate updates. Celcuity's lead candidate, gedatolisib, is a dual inhibitor targeting Class I PI3K isoforms and mTOR, with a Phase 3 study expected to begin in 2022 for HR+/HER2- advanced breast cancer. The CELsignia platform identifies patients likely to benefit from targeted therapies.

Positive

• Upcoming release of Q2 2022 financial results, possibly indicating improved metrics.
• Initiation of Phase 3 study for gedatolisib in 2022, indicating progress in drug development.
• Unique CELsignia diagnostic platform may enhance patient targeting for therapies.

Negative

• None.

MINNEAPOLIS, MN / ACCESSWIRE / August 4, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers, today announced that it will release its financial results for the second quarter 2022 after the stock market close on Thursday, August 11, 2022. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-877-407-0784 and international callers should dial 1-201-689-8560 and reference conference ID: 13731012. A live webcast presentation can also be accessed using this weblink: https://viavid.webcasts.com/starthere.jsp?ei=1557419&tp_key=2043138d9a. A replay of the webcast will be available on the Celcuity website following the live event.

About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for hormonally driven cancers. The company's lead therapeutic candidate is gedatolisib, a potent, reversible dual inhibitor that selectively targets all Class I PI3K isoforms and mTOR. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. The company expects to initiate a Phase 3 study evaluating gedatolisib in patients with HR+/HER2- advanced breast cancer in 2022. Its CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com.

Contacts:

Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
763-392-0123

ICR Westwicke
Robert Uhl, robert.uhl@westwicke.com
(619) 228-5886

SOURCE: Celcuity Inc.

View source version on accesswire.com:
https://www.accesswire.com/710838/Celcuity-Inc-Schedules-Release-of-Second-Quarter-2022-Financial-Results-and-WebcastConference-Call

FAQ

When will Celcuity release its Q2 2022 financial results?

Celcuity will release its Q2 2022 financial results on August 11, 2022, after the market closes.

What is gedatolisib and how is it related to Celcuity?

Gedatolisib is Celcuity's lead therapeutic candidate, a dual inhibitor that targets Class I PI3K isoforms and mTOR for hormonally driven cancers.

What is the focus of Celcuity's Phase 3 study?

The Phase 3 study will evaluate gedatolisib in patients with HR+/HER2- advanced breast cancer.

What is the CELsignia platform?

CELsignia is a companion diagnostic platform that analyzes live patient tumor cells to identify groups likely to benefit from targeted therapies.